Literature DB >> 28978568

Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion.

Marcus A Carden1,2, Meredith E Fay1,2, Xinran Lu3, Robert G Mannino1,2, Yumiko Sakurai1,2, Jordan C Ciciliano1,4, Caroline E Hansen1,5, Satheesh Chonat1, Clinton H Joiner1, David K Wood3, Wilbur A Lam1,2.   

Abstract

Abnormal sickle red blood cell (sRBC) biomechanics, including pathological deformability and adhesion, correlate with clinical severity in sickle cell disease (SCD). Clinical intravenous fluids (IVFs) of various tonicities are often used during treatment of vaso-occlusive pain episodes (VOE), the major cause of morbidity in SCD. However, evidence-based guidelines are lacking, and there is no consensus regarding which IVFs to use during VOE. Further, it is unknown how altering extracellular fluid tonicity with IVFs affects sRBC biomechanics in the microcirculation, where vaso-occlusion takes place. Here, we report how altering extracellular fluid tonicity with admixtures of clinical IVFs affects sRBC biomechanical properties by leveraging novel in vitro microfluidic models of the microcirculation, including 1 capable of deoxygenating the sRBC environment to monitor changes in microchannel occlusion risk and an "endothelialized" microvascular model that measures alterations in sRBC/endothelium adhesion under postcapillary venular conditions. Admixtures with higher tonicities (sodium = 141 mEq/L) affected sRBC biomechanics by decreasing sRBC deformability, increasing sRBC occlusion under normoxic and hypoxic conditions, and increasing sRBC adhesion in our microfluidic human microvasculature models. Admixtures with excessive hypotonicity (sodium = 103 mEq/L), in contrast, decreased sRBC adhesion, but overswelling prolonged sRBC transit times in capillary-sized microchannels. Admixtures with intermediate tonicities (sodium = 111-122 mEq/L) resulted in optimal changes in sRBC biomechanics, thereby reducing the risk for vaso-occlusion in our models. These results have significant translational implications for patients with SCD and warrant a large-scale prospective clinical study addressing optimal IVF management during VOE in SCD.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Year:  2017        PMID: 28978568      PMCID: PMC5731085          DOI: 10.1182/blood-2017-04-780635

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   25.476


  59 in total

1.  Knockout-transgenic mouse model of sickle cell disease.

Authors:  T M Ryan; D J Ciavatta; T M Townes
Journal:  Science       Date:  1997-10-31       Impact factor: 47.728

Review 2.  Fluid replacement therapy for acute episodes of pain in people with sickle cell disease.

Authors:  Uduak Okomo; Martin M Meremikwu
Journal:  Cochrane Database Syst Rev       Date:  2015-03-12

3.  Autoxidation, dehydration, and adhesivity may be related abnormalities of sickle erythrocytes.

Authors:  R P Hebbel; P A Ney; W Foker
Journal:  Am J Physiol       Date:  1989-03

Review 4.  Hemoglobin S gelation and sickle cell disease.

Authors:  W A Eaton; J Hofrichter
Journal:  Blood       Date:  1987-11       Impact factor: 22.113

5.  Relative hematocrit in human skin capillaries and its relation to capillary blood flow velocity.

Authors:  B Fagrell; M Intaglietta; J Ostergren
Journal:  Microvasc Res       Date:  1980-11       Impact factor: 3.514

6.  Osmolality revisited--deriving and validating the best formula for calculated osmolality.

Authors:  A Khajuria; J Krahn
Journal:  Clin Biochem       Date:  2005-06       Impact factor: 3.281

7.  Normal saline is associated with increased sickle red cell stiffness and prolonged transit times in a microfluidic model of the capillary system.

Authors:  Marcus A Carden; Meredith Fay; Yumiko Sakurai; Brynn McFarland; Sydney Blanche; Caleb DiPrete; Clinton H Joiner; Todd Sulchek; Wilbur A Lam
Journal:  Microcirculation       Date:  2017-07       Impact factor: 2.628

8.  Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo.

Authors:  A Mozzarelli; J Hofrichter; W A Eaton
Journal:  Science       Date:  1987-07-31       Impact factor: 47.728

Review 9.  Coagulation abnormalities of sickle cell disease: Relationship with clinical outcomes and the effect of disease modifying therapies.

Authors:  Denis Noubouossie; Nigel S Key; Kenneth I Ataga
Journal:  Blood Rev       Date:  2015-12-24       Impact factor: 8.250

10.  Heterogeneous red blood cell adhesion and deformability in sickle cell disease.

Authors:  Yunus Alapan; Jane A Little; Umut A Gurkan
Journal:  Sci Rep       Date:  2014-11-24       Impact factor: 4.379

View more
  18 in total

1.  Small separation diffuse correlation spectroscopy for measurement of cerebral blood flow in rodents.

Authors:  Eashani Sathialingam; Seung Yup Lee; Bharat Sanders; Jaekeun Park; Courtney E McCracken; Leah Bryan; Erin M Buckley
Journal:  Biomed Opt Express       Date:  2018-10-25       Impact factor: 3.732

Review 2.  0.9% NaCl (Normal Saline) - Perhaps not so normal after all?

Authors:  Neil Blumberg; Jill M Cholette; Anthony P Pietropaoli; Richard Phipps; Sherry L Spinelli; Michael P Eaton; Suzie A Noronha; Jerard Seghatchian; Joanna M Heal; Majed A Refaai
Journal:  Transfus Apher Sci       Date:  2018-02-21       Impact factor: 1.764

3.  Patrolling monocytes scavenge endothelial-adherent sickle RBCs: a novel mechanism of inhibition of vaso-occlusion in SCD.

Authors:  Yunfeng Liu; Hui Zhong; Weili Bao; Avital Mendelson; Xiuli An; Patricia Shi; Stella T Chou; Deepa Manwani; Karina Yazdanbakhsh
Journal:  Blood       Date:  2019-05-10       Impact factor: 22.113

4.  The biophysics and mechanics of blood from a materials perspective.

Authors:  Yongzhi Qiu; David R Myers; Wilbur A Lam
Journal:  Nat Rev Mater       Date:  2019-03-28       Impact factor: 66.308

5.  Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain.

Authors:  Marcus A Carden; David C Brousseau; Fahd A Ahmad; Jonathan Bennett; Seema Bhatt; Amanda Bogie; Kathleen Brown; Theron Charles Casper; Laura L Chapman; Corrie E Chumpitazi; Daniel Cohen; Carlton Dampier; Angela M Ellison; Hartmut Grasemann; Robert W Hickey; Lewis L Hsu; Sara Leibovich; Elizabeth Powell; Rachel Richards; Syana Sarnaik; Debra L Weiner; Claudia R Morris
Journal:  Am J Hematol       Date:  2019-04-29       Impact factor: 10.047

Review 6.  Hyperviscosity syndromes; hemorheology for physicians and the use of microfluidic devices.

Authors:  Jamie O Musick; Kirby S Fibben; Wilbur A Lam
Journal:  Curr Opin Hematol       Date:  2022-07-18       Impact factor: 3.218

Review 7.  Microfluidics in vascular biology research: a critical review for engineers, biologists, and clinicians.

Authors:  Grigor Simitian; María Virumbrales-Muñoz; Cristina Sánchez-de-Diego; David J Beebe; David Kosoff
Journal:  Lab Chip       Date:  2022-09-27       Impact factor: 7.517

Review 8.  Microfluidic methods to advance mechanistic understanding and translational research in sickle cell disease.

Authors:  Melissa Azul; Eudorah F Vital; Wilbur A Lam; David K Wood; Joan D Beckman
Journal:  Transl Res       Date:  2022-03-27       Impact factor: 10.171

9.  Microfluidic electrical impedance assessment of red blood cell-mediated microvascular occlusion.

Authors:  Yuncheng Man; Debnath Maji; Ran An; Sanjay P Ahuja; Jane A Little; Michael A Suster; Pedram Mohseni; Umut A Gurkan
Journal:  Lab Chip       Date:  2021-03-05       Impact factor: 6.799

10.  Time to rethink haemoglobin threshold guidelines in sickle cell disease.

Authors:  Samir K Ballas; Frans A Kuypers; Victor R Gordeuk; Jane S Hankins; Alexis A Thompson; Elliott Vichinsky
Journal:  Br J Haematol       Date:  2021-06-15       Impact factor: 8.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.